You are here: Industry Insights > Vyondys 53

News List

Treatment for rare Duchenne muscular dystrophy mutation approved by FDA europeanpharmaceuticalreview
March 01, 2021
The FDA conditionally approved Sarepta’s Amondys 45 (casimersen) after interim Phase III results indicated the treatment is reasonably likely to be of clinical benefit.
FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation worldpharmanews
December 17, 2019
The U.S. Food and Drug Administration today granted accelerated approval to Vyondys 53 (golodirsen) injection to treat Duchenne muscular dystrophy (DMD) patients who ...
FDA Grants Accelerated Approval to Rare Duchenne Muscular Dystrophy Mutation Treatment americanpharmaceuticalreview
December 16, 2019
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Vyondys 53 (golodirsen) injection to treat Duchenne muscular dystrophy (DMD) patients who have ...
Sarepta’s DMD therapy Vyondys 53 secures FDA accelerated approval pharmaceutical-technology
December 16, 2019
Sarepta Therapeutics has secured accelerated approval from the US Food and Drug Administration (FDA) for Vyondys 53 (golodirsen) to treat duchenne muscular dystrophy (DMD) patients with ...